Investigating the Effects of Cannabidiol on Social Anxiety Disorder
ConditionPhobia, Social
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-55
SponsorMassachusetts Institute of Technology
About this trial
The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).
Eligibility criteria
Qualifiers
Ability and willingness to provide written informed consent.
Sufficiently fluent in English to participate in the trial.
Between 18-55 years of age (inclusive).
Right-hand dominant.
Disqualifiers
History of bipolar disorder, schizophrenia, psychosis, delusional disorders.
History of eating disorder within past 6 months.
History of any traumatic brain injury.
Currently diagnosed with diabetes mellitus.
Trial design
Treatments tested in this trial
- Cannabidiol
- Placebo
Treatment groups
50 Participants
are divided into 2 treatment groupsSponsors and collaborators
Massachusetts Institute of Technology
Lead sponsor
Massachusetts General Hospital
Collaborator
Source ClinicalTrials.gov